CLINICAL_TRIALS
trial_result
· 2020-11-18
Clinical Trial Update: Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma [Phase 1, Phase 2]
Summary
Clinical trial update for Gleevec/Taxol in uterine papillary serous carcinoma (phase 1/2) has terminated; results posted in 2020.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: M.D. Anderson Cancer Center | Conditions: Uterine Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-11-18